Research and Development: Comparing Key Metrics for Teva Pharmaceutical Industries Limited and Pharming Group N.V.

Teva vs. Pharming: A Decade of R&D Investment Trends

__timestampPharming Group N.V.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014141823531488000000
Thursday, January 1, 2015155030281525000000
Friday, January 1, 2016161835852111000000
Sunday, January 1, 2017223828491848000000
Monday, January 1, 2018330382061213000000
Tuesday, January 1, 2019317770401010000000
Wednesday, January 1, 202041464134997000000
Friday, January 1, 202167178053967000000
Saturday, January 1, 202252531000838000000
Sunday, January 1, 202368914000953000000
Monday, January 1, 2024998000000
Loading chart...

Unleashing the power of data

A Decade of R&D: Teva vs. Pharming

In the ever-evolving pharmaceutical industry, research and development (R&D) are pivotal for innovation and growth. Over the past decade, Teva Pharmaceutical Industries Limited and Pharming Group N.V. have demonstrated contrasting R&D investment strategies.

Teva, a global leader, consistently allocated substantial resources to R&D, peaking in 2016 with a 63% increase from 2014. However, a downward trend followed, with a 55% reduction by 2022. This shift reflects Teva's strategic realignment amidst industry challenges.

Conversely, Pharming Group N.V., a smaller player, steadily increased its R&D spending, achieving a remarkable 386% growth from 2014 to 2023. This commitment underscores Pharming's focus on niche markets and innovative therapies.

These trends highlight the diverse approaches within the pharmaceutical sector, where strategic R&D investments can significantly influence a company's trajectory and market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025